Oxidative stress mediated toxicity is common to several sight-threatening ocular conditions, in which vascular endothelial growth factor (VEGF) plays both a pathologic and protective role. Anti-VEGF therapy can negate the protective role of endogenous VEGF and enhance oxidative stress and thus should be administered with caution as long-term intravitreal usage of bevacizumab may have collateral negative effects on retinal cells.
